 |
|
|
| |
Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study
|
| |
| |
ID Week 2023 Oct 11
Charlotte-Paige Rolle MD MPH1,2, Jamie Castano MA1, Vu Nguyen M.S.1, Federico Hinestrosa MD1,3, Edwin DeJesus MD1,3
Orlando Immunology Center1, Department of Global Health, Emory University Rollins School of Public Health2, University of Central Florida College of Medicine3
|
| |
|
|
|
|
|
